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Abstract
Background: Clear cell sarcoma of the kidney (CCSK) is a rare malignant pediatric renal neoplasm with a heterogeneous
histological appearance which often results in misdiagnosis. There are no specific immunohistochemical markers which
can help in differentiating CCSK from other pediatric renal neoplasms. Recently Cyclin D1 has been investigated as a
possible marker in this regard. In this study, we aim to determine the usefulness of Cyclin D1 in differentiating between
CCSK and other pediatric renal neoplasms and to compare our results with those of recently published studies.
Methods: A total of 48 cases of CCSK, Wilms tumor (WT), renal rhabdoid tumor, mesoblastic nephroma, renal Ewing
sarcoma and neuroblastoma were included in the study. All cases were stained with cyclin D1. Extent of Cyclin D1
staining was graded according to percentage of positive tumor cells as diffuse (> 70%), focal (5 to 70%), and negative (<
5%). Intensity of Cyclin D1 staining was graded as strong or 3+, moderate or 2+ and weak or 1 + .
Results: Most or all cases of CCSK, neuroblastoma and renal Ewing sarcoma demonstrated diffuse and strong positivity
for Cyclin D1. Most cases of Wilms tumor (epithelial component) also demonstrated diffuse and often strong positivity for
Cyclin D1. In most cases of WT, blastemal component was negative.
Conclusions: Cyclin D1 is a sensitive but not specific immunohistochemical marker for CCSK and many other pediatric
renal malignant neoplasms as well as for neuroblastoma. Hence, careful examination of histological features is important
in reaching an accurate diagnosis in CCSKs. However, Cyclin D1 is very helpful in distinguishing between blastema-rich
WT and CCSK.
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Background
Clear cell sarcoma of kidney (CCSK) is an uncommon
mesenchymal renal tumor of uncertain histogenesis which
comprises approximately 3 to 4% of malignant pediatric
renal neoplasms. It occurs in young children and mean
age at diagnosis is approximately 36months. It is more
common in males (male to female ratio is 2:1), is centered
in the renal medulla and is almost always unifocal. It is
usually circumscribed but unencapsulated with a tan, soft
cut surface and most tumors are quite large in size. On
histological examination, classic CCSK is characterized by
nests or cords of epithelioid cells with round to oval
nuclei. Myxoid pools and thin and regularly branching fi-
brovascular septa separate the cords of tumor cells [1–6].
However, CCSK is very heterogeneous and diverse in
histological appearance and a number of variant histo-
logical patterns may be seen. It has a propensity to
metastasize to bone, and “bone metastasizing renal tumor
of childhood” is one of its synonyms [7]. In the past, its
prognosis was poor but since the addition of doxorubicin
to chemotherapeutic protocols (previously comprising
vincristine and dactinomycin) secondary to the results of
the first three National Wilms Tumor Study (NWTS) trials,
survival has increased from 20 to 70%. All patients with
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CCSK, regardless of stage, are now treated with doxorubi-
cin. Brain metastases have now become more common
than bone metastases [2, 5, 8, 9]. Approximately 10% of
CCSKs demonstrate a rearranging chromosomal transloca-
tion i.e. t(10,17) (q22;p13) resulting in YWHAE-FAM22-
NUTM2B/E gene fusion which is also seen in high grade
endometrial stromal sarcoma. Recently, CCSK has also
been shown to consistently demonstrate BCOR gene ab-
normalities including exon 15 internal tandem duplica-
tions and BCOR-CCNB3 gene fusion which distinguish it
from other pediatric renal tumors. Metastases can occur
as late as ten years after initial diagnosis. Owing to the
essential role of doxorubicin in the therapy of CCSK, it is
imperative that pathologists identify it accurately. Failure
to do so can prevent a child from getting optimal chemo-
therapy [10–18].
Owing to its marked histological heterogeneity, CCSK
can be mimicked by a number of malignant pediatric renal
and extrarenal neoplasms including blastema-rich Wilms
Tumor (WT), mesoblastic nephroma, neuroblastoma etc.
It is often difficult to diagnose CCSK from these tumors on
morphology alone [3, 5]. Until recently, there were no
specific immunohistochemical markers that reliably distin-
guished CCSK from other pediatric renal neoplasms [5].
Thus, it was sometimes difficult to diagnose CCSK accur-
ately (in spite of the therapeutic and prognostic importance
of an accurate diagnosis). Molecular tests for detecting
BCOR gene abnormalities are not available especially in
developing countries such as ours. Recently, a number of
studies have suggested that immunohistochemical stain
Cyclin D1 is useful in distinguishing CCSK from some
pediatric renal neoplasms [3, 5, 19]. More importantly,
recent studies suggest that BCOR immunohistochemistry
appear to be highly sensitive and specific for the diagnosis
of CCSK based on the recently identified BCOR gene
abnormalities. BCOR immunohistochemistry appears to be
more specific than Cyclin D1 [14, 15].
The aim of the present study was to determine the
usefulness of Cyclin D1 in distinguishing CCSK from
other pediatric renal neoplasms and to see whether our
findings match those in other recently published studies.
Methods
Study cohort
The surgical pathology files of the Section of Histopath-
ology, Department of Pathology and Laboratory Medicine,
Aga Khan University Hospital and cases were submitted
from French Medical Institute for Mothers and Children
were searched for cases of CCSK, WT (nephroblastoma),
renal rhabdoid tumor (RT), congenital mesoblastic
nephroma, Ewing sarcoma of kidney as well as retroperi-
toneal neuroblastoma reported over a ten year period i.e.
January 1, 2008 and December 31, 2017. A total of 48
cases were included in the study. These included 19 cases
of CCSK, 9 cases of WT and 4 cases each of renal RT,
Mesoblastic nephroma and Ewing sarcoma. In addition, 8
cases of neuroblastoma were also included. Although neu-
roblastomas are not renal tumors but are retroperitoneal
like the former and occur in the same age group as
pediatric renal tumors. Due to these features they need to
be distinguished from pediatric renal tumor. Hence, they
were included in the study.
Immunohistochemistry
All cases were reviewed by the two principal authors (NU
and ZA). A number of immunohistochemical markers in-
cluding Vimentin (Flex Monoclonal Mouse Antivimentin,
clone V9, ready to use, DAKO, Glostrup, Denmark), Anti-
smooth muscle actin (Flex Monoclonal Mouse Antismooth
muscle actin, clone 1A4, ready to use, DAKO, Glostrup,
Denmark), S100 protein (Flex Polyclonal Mouse Anti-S100,
ready to use, DAKO, Glostrup, Denmark), CD99 (Flex
Monoclonal Mouse Anti human CD99, clone V9, clone
12E7,ready to use, DAKO, Glostrup, Denmark), WT1 (Flex
Monoclonal Mouse Antihuman, Wilms Tumor 1 (WT1)
protein, clone 6F-H2–7, ready to use, DAKO, Glostrup,
Denmark), Neurofilament (Flex Monoclonal Mouse
Antihuman neurofilament protein, clone 2F11, ready to
use, DAKO, Glostrup, Denmark), CD56 (Flex Monoclonal
Mouse Antihuman CD56, clone 1223C3, ready to use,
DAKO, Glostrup, Denmark), Synaptophysin (Flex Mono-
clonal Mouse Antihuman synaptophysin, clone DAKO
SYNAP, ready to use, DAKO, Glostrup, Denmark), Desmin
(Flex Monoclonal Mouse Antihuman desmin, clone D33,
ready to use, DAKO, Glostrup, Denmark), Cytokeratin
AE1/AE3 (Flex Monoclonal Mouse Antihuman cytokera-
tin, clone AE1/AE3, ready to use, DAKO, Glostrup,
Denmark), Epithelial membrane antigen (Flex Monoclonal
Mouse Antihuman epithelial membrane antigen, clone
E29, ready to use, DAKO, Glostrup, Denmark) were per-
formed in different cases at the time of initial reporting and
were reviewed by the authors. Cyclin D1 (Flex Monoclonal
Rabbit Antihuman Cyclin D1, clone EP12, ready to use,
DAKO, Glostrup, Denmark) was retrospectively performed
in all 48 cases. The staining for Cyclin D1 was performed
on DAKO automated immunostainer. The antibody was
optimized using Ventana DAB detection kit (Ventana Med-
ical Systems) and standard quality control procedures were
performed. Cyclin D1 staining was performed following
heat induced antigen retrieval using ER2 antigen retrieval
buffer. Cases of mantle cell lymphoma were used as
positive control. Negative controls were also used. For the
purpose of study, extent of Cyclin D1 staining was graded
according to percentage of positive tumor cells as diffuse
(> 70%), focal (> 5 to 70%) or negative (< 5%); intensity of
staining was graded as strong or 3+ (nuclear intensity
similar to that of mantle cell lymphoma control), moderate
or 2+ (definite nuclear staining weaker than 3+ but easily
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identifiable at × 40 magnification) and weak or 1+ (nuclear
staining identifiable only at high power magnification). This
scale for extent and grading was based on that used in two
studies published in 2015 [3, 5]. All cyclin D1 stained slides
were also reviewed by the two principal authors (NU and
ZA). All data was analyzed in SPSS software version 19.
Results
A total of 48 cases were included in the study. These in-
cluded 19 cases of CCSK, 9 cases of WT and 4 cases each
of renal RT, Mesoblastic nephroma and Ewing sarcoma.
In addition, 8 cases of neuroblastoma were also included.
Patients with CCSK ranged in ages from 1 to 29 years
with means and median age of 5.5 and 3 years respectively.
Of the 19 patients, 13 (68.4%) were males while 6 (31.6%)
were females. Tumor was located in left and right kidney
in 8 cases each. In 3 cases, laterality was not known.
Tumor size ranged from 8 cm to 14.5 cm with mean
tumor size of 11 cm in greatest dimension.
All 19 cases of CCSK demonstrated reactivity for Cyclin
D1. In 13 cases (68.4%), intensity of staining was 3+, in 4
cases (21%), intensity was 2+, while in 2 cases (10.5%), it
was 1+. Extent of staining ranged from 5 to 90% with aver-
age extent of staining being 54.5% (Fig. 1A,B). Extent of
staining was 60% in 11 cases (57.9%), 50% in 3 cases
(15.8%) and 90% in 1 case (5.3%). The clinical details as
well as details of Cyclin D1 staining intensity and extent
as well as details of other immunohistochemical markers
are shown in Table 1.
Of the 9 patients with WT, 6 (66.7%) were females,
while 3 (33.3%) were males. Ages ranged from 2.5 to 7
years. Mean and median ages were 4.5 and 4 years
respectively. In 6 patients (66.7%), tumor was located in
the left kidney while in 3 (33.3%), tumor was located in
the right kidney. Tumor size was available in 8 out 9
cases and ranged from 7.5 to 17.4 cm in largest dimen-
sion with mean tumor size of 11.5 cm.
Out of 9 cases of renal WT, 2 did not show any epithe-
lial component and tumor was composed entirely of blas-
tema and stromal components (biphasic). In these 2 cases,
Cyclin D1 was negative in both components in 1 case, and
showed weak positivity in blastemal component in the
other case. The remaining 7 cases showed strong (3+)
positivity in the epithelial component (tubules), while
blastemal component was negative in all cases. Extent of
staining ranged from 5 to 70%. Average extent of staining
was 37.5% (Fig. 2 A,B). The details are shown in Table 2.
Ages of the 4 patients with congenital mesoblastic
nephroma ranged from 15 days to 2months. Out of 4
patients, 3 (75%) were males while 1 (25%) was female.
Tumor was located in right kidney in 3 cases (75%) and
left kidney in 1 case (25%). Tumor size ranged from 7 to
9 cm with mean size of 8 cm in largest dimension.
Out of 4 cases of congenital mesoblastic nephroma, 3
were cellular type and 1 was of mixed type and all dem-
onstrated reactivity for Cyclin D1. Intensity of staining
was 3+ in all 4 cases. Extent of staining ranged from 10
to 50% and average extent of Cyclin D1 staining was
30% (Fig. 2C, D). Anti-smooth muscle actin was
performed in in 3 cases and was positive in all 3 cases.
Patients with renal RT ranged from 1 year to 14 years
in age with mean and median age of 4 and 1.5 years
respectively. Of the 4 patients, 3 (75%) were males and 1
(25%) was female. Tumor was located in left kidney in 2
cases (66.7%) and in right kidney in 1 case (33.3%).
Tumor laterality was not known in 3 cases. Tumor size
ranged from 7 cm to 9 cm in maximum dimension.
Mean tumor size was 7.5 cm.
Out of 4 cases of renal RT, 3 (75%) demonstrated
reactivity for Cyclin D1, intensity of staining was 2+ in
all 3 cases while extent of staining ranged from 10 to
Fig. 1 Classic clear cell sarcoma of kidney (a), showing diffuse strong Cyclin D1 positivity (b)
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Table 1 Clinical details and results of immunohistochemical staining with Cyclin D1 and other IHC markers in clear cell sarcoma of
kidney (n = 19)
Age (years) Sex Site Size (cm) Cyclin D1
staining Intensity
Cyclin D1 staining
proportion
ASMA Desmin S100 CKAE1 Vimentin EMA Bcl2 WT1 CD99
2 M R NK 2 60 -ve -ve -ve -ve +ve NP NP NP NP
29.5 M R 12 1 5 -ve NP NP -ve +ve -ve NP NP NP
4 M L 14.5 2 50 NP NP NP -ve +ve NP NP NP NP
4 M L 12.5 3 60 NP –ve NP -ve +ve NP NP NP NP
2 M R 9 3 50 -ve -ve -ve -ve +ve NP +ve NP NP
3 F NK NK 3 60 NP -ve NP -ve +ve -ve +ve -ve -ve
2 M L 13.5 3 60 NP NP NP -ve NP NP +ve -ve -ve
1 M R 7.5 3 60 NP NP NP NP +ve -ve +ve -ve -ve
1 M L 8 1 5 -ve -ve -ve -ve +ve NP NP -ve NP
5 M L 13 3 50 NP NP NP -ve +ve -ve NP -ve +ve
3 M L 10 3 60 NP NP NP -ve +ve -ve +ve -ve NP
2.5 M L 15 3 60 NP NP NP -ve +ve -ve +ve -ve NP
25 M L 12 3 60 NP NP NP -ve +ve -ve NP NP -ve
5 F R 9.3 3 60 NP -ve NP -ve +ve NP NP NP NP
1 F R 7.5 2 20 NP -ve NP NP NP NP NP -ve +ve
5 F R 9.9 3 60 NP NP NP -ve +ve -ve +ve NP NP
3 F NK 17 3 60 NP NP -ve -ve +ve NP NP NP NP
1 F R 7.5 2 15 NP -ve NP NP NP NP NP -ve Patchy +ve
1 M NK 10 3 90 NP NP NP -ve +ve NP NP -ve +ve
IHC: immunohistochemical; ASMA: Anti-smooth muscle actin; M: Male; F: female; R: Right; L: Left; NK: not known; NP: Not performed
Fig. 2 Classic Wilms tumor of kidney with epithelial and blastemal component (a). Cyclin D1 is strongly positive in the tubules while blastemal
component shows rare positivity (b). Cellular congenital mesoblastic nephroma exhibiting trapped renal tubules (c), showing moderate to
marked staining for Cyclin D1 (d)
Uddin et al. Diagnostic Pathology           (2019) 14:13 Page 4 of 8
Table 2 Clinical details and results of immunohistochemical staining with Cyclin D1 and other IHC markers in Wilms tumor (n = 9)
Age (years) Sex Side Size (cm) Wilms tumor component Cyclin D1
Intensity
Cyclin D1
Proportion (%)
Desmin CKAE1/AE3 WT1 CD99
3 F NK NK Blastema & stroma only;
no epithelium
-ve -ve Focal +ve NP +ve NP
2.6 F L 17.5 Tubules 3 +ve 70 NP NP NP NP
Blastema -ve
3 F R 8 Tubules 3 +ve 50 NP NP NP NP
Blastema -ve
6 F R 10 Tubules 3 +ve 5 NP NP NP NP
Blastema -ve
5 F L 15 Tubules -ve -ve Patchy+ -ve Patchy +ve -ve
Blastema -ve
4.5 F L 7.5 Tubules 3 +ve 20 NP NP +ve NP
Blastema -ve
4 M - 14 Tubules 3 +ve 40 NP NP NP NP
Blastema -ve
7 M L 12 Tubules 3 +ve 45 +ve +ve +ve NP
Blastema -ve
6 M R 9 Tubules 3 +ve 40 -ve NP +ve NP
Blastema -ve
IHC immunohistochemical, M Male, F female, R Right, L Left, NP Not performed, NK Not known
Fig. 3 Renal Ewing sarcoma exhibiting (a) mild to moderate staining of Cyclin D1 (b). Neuroblastoma with central neuropil (c), showing diffuse strong
Cyclin D1 positivity (d)
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30%. Average extent of staining was 20%. Vimentin was
positive in all 4 cases. EMA was performed in 3 cases
and was positive in all 3. All 4 cases showed loss of
INI 1.
The ages of 4 patients with renal Ewing sarcoma ranged
from 2 to 36 years with mean and median age of 20 and
35 years respectively. Of the 4 patients, 2(50%) were males
and 2 (50%) were females. Of the 4 cases, 3 were located
in the right kidney (75%) while 1 (25%) was located in the
left kidney (25%). Tumor size ranged from 2.5 to 17 cm in
largest dimension. Mean tumor size was 11.7 cm.
Out of the 4 cases of renal Ewing sarcoma, 3 (75%)
demonstrated staining for Cyclin D1. Of these 3 cases,
intensity of staining was 3+ in 2 cases (66.7%) and 2+ in
1 case (33.3%). Extent of staining ranged from 10 to
30%. Average extent of Cyclin D1 staining was 16.7%
(Fig. 3A,B). CD99 was positive in all 4 cases.
We also included 8 cases of neurobastomas in our
study. These 8 patients ranged from 0.9 to 25 years in age.
Mean and median ages were 9 and 6 years respectively. Of
the 8 patients, 5 (62.5%) were females while 3 (37.5%)
were males.
Out of 8 cases of neuroblastoma in our series,
8(88.9%) demonstrated intense 3+ reactivity for Cyclin
D1. Extent of Cyclin D1 staining ranged from 5 to 70%.
Average extent of staining was 37.5% (Fig. 3 C, D). The
details of Cyclin D1 staining are shown in Table 3.
Discussion
All 19 cases of CCSK in our study demonstrated positivity
for Cyclin D1 which was very intense (3+) in over 68% of
cases and moderately intense (2+) in 21%. Thus over 89%
cases showed moderate to marked intensity. Average ex-
tent of staining was almost 55%. These findings were indi-
cative of diffuse and strong nuclear positivity for Cyclin
D1 in the large majority of CCSK and were similar to the
findings in other recent studies by Aw et al. (3) and
Mirkovic et al. [5] which also showed moderate to severely
intense diffuse positivity for Cyclin D1 in 7 out of 8 cases
and all 14 cases respectively. These results demonstrate
that Cyclin D1 is a very sensitive marker for CCSK.
All 4 cases of congenital mesoblastic nephroma (CMN)
in our study showed markedly intense (3+) focal to diffuse
staining for Cyclin D1. All 11 cases of CMN in Mirkovic
et al’s study showed focal (4 cases) to diffuse (17 cases)
moderate to severely intense Cyclin D1 staining [5]. This
shows that Cyclin D1 is not useful in distinguishing be-
tween CCSK and CMN. CMN has distinct morphologic
features with uniform fascicles of spindle cells that help in
differentiating it from CCSK [3]. Molecular methods can
also help (the cellular form of CMN can mimic CCSK
morphologically but its distinct translocation can be iden-
tified by PCR) [20].
Similarly, 7 out of 9 cases of WT in our study demon-
strated intense 3+ staining for Cyclin D1 in their epithelial
component with average extent of staining of almost 40%.
All 4 cases of NB in Mirkovic et al.’s study also demon-
strated diffuse moderate to strong nuclear staining for Cyc-
lin D1 [5]. Thus, Cyclin D1 is verye useful in distinguishing
between CCSK and WT in cases in which blastema pre-
dominates (blastema-rich WT), as Cyclin D1 will highlight
the epithelial component. Since the prognosis and therapy
of CCSK and WT are different, it is important to distin-
guish between the two and incidentally the most difficult
morphologic distinction in the differential diagnosis of
CCSK is blastema-rich WT [5].
Of the 4 cases of renal Ewing sarcoma in our series, 3
(75%) demonstrated focal to diffuse staining for Cyclin D1
which was very intense in 2 cases. All 5 cases of renal
Ewing sarcoma in the study by Mirkovic et al. [5] showed
focal (1 case) to diffuse (4 cases) staining of variable inten-
sity for Cyclin D1. Thus Cyclin D1 cannot reliably distin-
guish between CCSK and Ewing sarcoma. The latter
however has a distinct morphologic appearance and a
specific translocation i.e. t(11,22) seen in about 85% of
cases which can help in distinguishing it from CCSK [21].
Table 3 Clinical details and results of immunohistochemical staining with Cyclin D1 and other IHC markers in neuroblastoma (n = 8)
Age (years) Sex Site Cyclin D1
Intensity
Cyclin D1
proportion
Synaptophysin Neurofilament CD56 Desmin S100 CKAE1/AE3 Vimentin WT1 CD99
25 F Pelvis 3 40 +ve +ve +ve NP -ve -ve NP NP NP
10 F Left kidney 3 90 +ve +ve +ve -ve +ve -ve Patchy
+ve
Patchy
+ve
NP
1 F Pelvis 3 5 +ve +ve +ve -ve NP NP Focal
+ve
-ve NP
.5 M Kidney 3 80 +ve +ve +ve NP NP NP NP NP NP
6 M Sacroccocyx 3 70 +ve -ve +ve -ve NP -ve NP NP -ve
10 M Inguinal LN 3 90 +ve NP +ve NP NP NP NP NP -ve
8 F Adrenal 3 90 +ve NP NP -ve NP NP NP NP -ve
0.9 F Presacral 3 90 +ve +ve +ve -ve NP NP NP NP NP
NP: Not performed; LN: Lymph node; M:Male;F:Female
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Of the 4 cases of renal RT in our study, 3 (75%) showed
moderately intense staining for Cyclin D1 which ranged in
extent from 10 to 50% with average extent of staining of
30%. This finding is in contrast to the results in the study
by Mirkovic et al. [5]. Of the 4 cases of RT in their study,
2 were negative, while the other 2 showed focal sparse nu-
clear staining for Cyclin D1. Both Mirkovic et al. [5] and
Aw et al. [3] believe that Cyclin D1 is useful in differentiat-
ing CCSK from renal RT but our findings indicate other-
wise. However, number of cases of renal RT in our study
was very small to derive any definite conclusions. In
equivocal cases, the loss of nuclear positivity for INI 1
immunohistochemical marker in RT can be helpful in
differentiating it from CCSK [22]. All 4 cases of RT in our
study showed loss of INI 1.
All 8 cases of neuroblastoma in our study demonstrated
intense 3+ staining for Cyclin D1 which ranged in extent
from as low as 5% to as high as 90%. In fact, 6 out of 8
cases (75%) showed diffuse 3+ positivity which ranged in
extent between 70 and 90%. This finding is similar to the
findings by Mirkovic et al. [5] and Aw et al. [3] and con-
firms their results that Cyclin D1 immunohistochemistry
cannot be used to reliably distinguish CCSK from
Neuroblastoma.
As discussed by both Mirkovic et al. [5] and Aw et al.
[3], Cyclin D1 is negative or shows only rare or sparse nu-
clear positivity in the diffuse blastematous and stromal
components of WT while epithelial component may show
strong and diffuse nuclear positivity or may even be nega-
tive. In our study, 7 out of 9 cases of WT demonstrated
intense (3+) Cyclin D1 positivity in the epithelial compo-
nent and extent of staining averaged around 40%. Cyclin
D1 is thus helpful in differentiating CCSK from blastema-
dominant WT which mimics CCSK morphologically.
Although Cyclin D1 is positive in both CCSK and the epi-
thelial component of WT, the two can usually be differen-
tiated from each other by their morphological features
which are distinct. Thus our findings, in relation to Cyclin
D1 positivity in WT were similar.
Conclusions
Cyclin D1 is a sensitive but not specific immunohisto-
chemical marker for CCSK and many other pediatric renal
malignant neoplasms as well as for neuroblastoma. Hence,
careful examination of histological features is important in
reaching an accurate diagnosis in CCSKs. Cyclin D1
however is very helpful in distinguishing between CCSK
and blastema-rich WT which is arguably the most difficult
morphologic distinction in the differential diagnosis of
CCSK. Our results were similar to two other recently pub-
lished studies [3, 5]. However, the small number of cases
is a limitation of our study. Larger studies are recom-
mended in order to verify and validate these results.
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